Development of Antibody for Gene Therapy
Based on "integrated R&D platform for innovative antibody drugs" and "super-trillion innovative antibody discovery platform". We can customize the screening strategies for the best antibody candidates suitable for gene therapy. We also provide all-in-one R&D services from target to gene therapeutic antibody.
Service Highlights
1. Integrated platform for innovative antibody drug discovery
l 10 functional modules and 25+ sub-platforms covering the whole procedure of drug discovery
l Project with comprehensive arrangement; PCC can be completed in 12 months
2. Distinctive capability for multi-route antibody discovery
l Trillion-capacity antibody library; thousands of leads can be obtained for common targets
l Diversified antibody sources: human recombinant library, semi-synthetic trillion-capacity VHH library, mouse immune library, alpaca immune VHH library, polypeptide library, and common light chain library
l Full coverage of antibody types: full human antibody, single domain antibody, common light chain bispecific antibody, mouse monoclonal antibody, and rat monoclonal antibody
l Antibody types: IgG, Fab, VHH
3. Extensive project experience
l 20+ scientists expertized in various fields with the capability of systematic review of specific project
l 100+ projects experience and high success rate
4. Customized service
l Combination of innovative target / linker / intracellular nucleic acid
l Integrated service platform in the antibody development
Popular articles
SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.
Learn moreAfter the base is put into operation, SMOC’s capability to provide genetically modified rat/mouse models and technical services including gene function research and drug development will be greatly enhanced.
Learn more